Inventaire - your friends and communities are your best library

Incretin-based therapies: where will we be 50 years from now?

published in: Diabetologia

date of publication: 2015-05-21

Cites articles 21

Date

Title

Authors

2015-03-01

GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7.

Daniel J. Drucker
2014-09-01

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with typ

John Buse
2014-12-08

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.

Christoffer Clemmensen, Jonathan Campbell, Matthias Tschöp, Katrin Fischer, Sabine Uhles, Paul T Pfluger, Daniel J. Drucker
2014-05-01

Cardiovascular actions of incretin-based therapies

Daniel J. Drucker
2014-09-23

GLP-1 as a Mediator in the Remission of Type 2 Diabetes After Gastric Bypass and Sleeve Gastrectomy Surgery

Sten Madsbad, Jens Juul Holst
2014-02

Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery

Carsten Dirksen, Sten Madsbad, Jens Juul Holst
2013-06-08

Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?
2013-07-01

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study
2013-06-01

Exenatide and the treatment of patients with Parkinson's disease

Patricia Limousin, Thomas Foltynie, Andrew John Lees, Atbin Djamshidian, John Dickson, Iciar Aviles Olmos, Zinovia Kefalopoulou, Richard Wyse
2012-09-04

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
2012-03-26

Bariatric surgery versus conventional medical therapy for type 2 diabetes

Giovanni Ghirlanda
2011-01-01

Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications
2011-06-24

Management of type 2 diabetes: new and future developments in treatment

Clifford J Bailey
2011-05-18

Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function

Jens Juul Holst, Sten Madsbad, Urd Kielgast
2009-10-23

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

Arne Astrup, Stephan Rössner
2007-10-01

The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.

Jens Juul Holst, Steven E. Kahn, Carolyn F. Deacon, Santica M Marcovina
2004-12-01

Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide
2004-11-01

GIP as a potential therapeutic agent?
2001-07-01

Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

Jens Juul Holst
1993-08-01

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

Jens Juul Holst
1986-01-01

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

Article - wd:Q39004418

Welcome to Inventaire

the library of your friends and communities

learn more